IS THE HEALTH UTILITIES INDEX VALID AND RESPONSIVE IN ASSESSING PATIENTS WITH ANKYLOSING SPONDYLITIS?

Author(s)

Katherine Gooch, MSc, Assistant Director1, David H Feeny, PhD, Senior Investigator2, Robert Wong, MD, Medical Director3, Aileen Pangan, MD, Medical Director1, Dennis Revicki, PhD, Director4, Desiree van der Heijde, MD, Dr51Abbott Laboratories, Abbott Park, IL, USA; 2 Kaiser Permanente Center for Health Research, Portland, OR, USA; 3 Abbott Laboratories, Parsippany, NJ, USA; 4 United BioSource Corporation, Bethesda, MD, USA; 5 Leiden University Medical Center, Leiden, Netherlands

OBJECTIVES: QALYs are an important outcome used in cost-effectiveness analysis. The Health Utilities Index Mark 3 (HUI-3) is a self-reported measure covering 8 attributes of health status. Our objective was to assess construct validity and responsiveness of HUI-3 in ankylosing spondylitis (AS). METHODS: Data were derived from the Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS (ATLAS). We specified a priori hypotheses regarding the direction and magnitude of associations expected between overall and single-attribute HUI-3 scores and other health status and quality of life measures — SF-36, ASQOL, Bath AS Functional Index (BASFI), Bath AS Disease Activity Index (BASDAI), and Patient's Global Assessment (PGA). Using baseline data, we calculated correlation coefficients and interpreted them via guidelines suggested by Guyatt for negligible, weak, moderate, and strong associations. Responsiveness was assessed by calculating standardized response means (SRMs) of HUI-3 scores from baseline to Week 24 for patients meeting the minimum clinically important differences (MCID) for the ASQOL (–1.8). Responsiveness analysis was limited to patients with 24-week HUI-3 scores. RESULTS: A total of 295 of the 315 patients enrolled in ATLAS were included in the analysis. Mean age was 43 years, 76.3% were male, and mean duration of AS was 11 years. Correlation coefficients between HUI-3 scores and other instruments confirmed 62.2% of the a priori hypothesis, with an additional 24.5% being under- or over-estimated by only one category. Results of responsiveness analysis demonstrated that there were significant differences in overall HUI-3 (SRM 1.13) and most single-attribute change scores for patients whose changes were greater than the ASQOL MCID vs. those whose changes were

Conference/Value in Health Info

2009-05, ISPOR 2009, Orlando, FL, USA

Value in Health, Vol. 12, No. 3 (May 2009)

Code

PMS43

Topic

Patient-Centered Research

Topic Subcategory

Health State Utilities

Disease

Multiple Diseases, Musculoskeletal Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×